Literature DB >> 2740841

Sucralfate in the treatment of reflux esophagitis in children. Preliminary results.

F Argüelles-Martín1, F González-Fernández, M G Gentles, M Navarro-Merino.   

Abstract

In order to evaluate the use of sucralfate in the treatment of children with reflux esophagitis, we studied 66 children aged from 4 months to 12 years (mean 5.9 years, SD 3.5) diagnosed to have gastroesophageal reflux by means of esophageal isotopic examination and radiology. An endoscopic examination was carried out in all cases. None of the patients suffered from kidney disease or had taken antacids, cimetidine, sucralfate or antirheumatic drugs in the two weeks prior to the study. Patients were divided into three groups matched according to age, grade of esophagitis, sex, nutritional state and semiology and treated with sucralfate in tablets, cimetidine, or sucralfate in suspension; no dietetic or postural measures were used. On days 14, 28, 42 and 56, clinical control was carried out and endoscopy was done on day 28, this being repeated on day 56 if the course was not satisfactory. From the statistical analysis of the results we deduce that there are no differences between the three groups. Therefore sucralfate appears to be a useful drug for the treatment of children with esophagitis due to GER.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2740841

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  2 in total

1.  Diagnosis and treatment of gastroesophageal reflux disease in infants and children.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 2.  A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN).

Authors:  Y Vandenplas; A Ashkenazi; D Belli; N Boige; J Bouquet; S Cadranel; J P Cezard; S Cucchiara; C Dupont; K Geboes
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.